Consensus Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21.98 ^USD	-0.54%		-3.60%	-26.66%

Apr. 16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
Apr. 11	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Rocket Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

99a657edc.yLkHUXyfHTC1fXU6sSfFOSbszP-DZAc5pAaZxpNS2O0.muAqPSXqaHr2PjgD2Hf1aEOfp7HpVHZ-yGrDnL4mioGMiUYETq9LAt0TTQ~e040886194269cafcb231c5b7f73df79

Analyst Recommendations on Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65	23-10-24	MT
Needham Adjusts Rocket Pharmaceuticals' Price Target to $53 From $60, Keeps Buy Rating	23-09-13	MT
Canaccord Genuity Adjusts Price Target on Rocket Pharmaceuticals to $47 From $49, Maintains Buy Rating	23-08-11	MT
Stifel Adjusts Price Target on Rocket Pharmaceuticals to $48 From $53, Keeps Buy Rating	23-08-10	MT
Chardan Adjusts Rocket Pharmaceuticals' Price Target to $61 From $63, Keeps Buy Rating	23-05-08	MT
Raymond James Adjusts Price Target on Rocket Pharmaceuticals to $35 From $33, Maintains Outperform Rating	23-05-05	MT
UBS Adjusts Rocket Pharmaceuticals' Price Target to $56 From $60, Maintains Buy Rating	23-03-15	MT
Chardan Adjusts Price Target on Rocket Pharmaceuticals to $63 From $65, Keeps Buy Rating	23-03-01	MT
Morgan Stanley Initiates Rocket Pharmaceuticals at Overweight With $45 Price Target	23-02-01	MT
SVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $49 From $50, Maintains Outperform Rating	23-01-23	MT
BofA Securities Cuts Price Target on Rocket Pharmaceuticals to $35 From $38, Maintains Buy Rating	22-12-23	MT
SVB Securities Adjusts Rocket Pharmaceuticals' Price Target to $54 From $56, Keeps Outperform Rating	22-12-06	MT
Canaccord Genuity Starts Rocket Pharmaceuticals at Buy With $53 Price Target	22-11-08	MT
UBS Adjusts Rocket Pharmaceuticals Price Target to $60 From $62, Maintains Buy Rating	22-11-07	MT
Raymond James Adjusts Rocket Pharmaceuticals' Price Target to $33 From $34, Keeps Outperform Rating	22-11-07	MT
Needham Adjusts Price Target on Rocket Pharmaceuticals to $60 From $62, Maintains Buy Rating	22-11-04	MT
BTIG Initiates Rocket Pharmaceuticals at Buy With $35 Price Target	22-11-01	MT
Raymond James Adjusts Price Target on Rocket Pharmaceuticals to $34 From $24, Keeps Outperform Rating	22-10-03	MT
Chardan Lifts Price Target on Rocket Pharmaceuticals to $65 From $62, Maintains Buy Rating	22-09-30	MT
Evercore ISI Adjusts Rocket Pharmaceuticals Price Target to $75 From $65, Maintains Outperform Rating	22-09-30	MT
UBS Adjusts Rocket Pharmaceuticals Price Target to $62 From $68, Maintains Buy Rating	22-09-27	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.98 USD

Average target price

50.31 USD

Spread / Average Target

+128.88%

High Price Target

65 USD

Spread / Highest target

+195.72%

Low Price Target

39 USD

Spread / Lowest Target

+77.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Rocket Pharmaceuticals, Inc.

Goldman Sachs
UBS
Cantor Fitzgerald
Needham & Co.
Canaccord Genuity
Stifel Nicolaus
Chardan Research
Raymond James
Morgan Stanley
SVB Securities LLC
BofA Securities
BTIG
Evercore ISI
Stifel FirstEnergy
Chardan
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar